Palatin Technologies is a biopharmaceutical company that develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company’s leading product is Bremelanotide, which is used to treat hypoactive sexual desire disorder (HSDD). It has completed pivotal Phase 3 clinical trials. Palatin also has development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis. It was founded in 1986 and is based in Cranbury, New Jersey.